Resectable Stage II-IIIa Squamous NSCLC Clinical Trials in Shanghai, Shanghai Municipality

Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC